Incidence, determinants and impact of acute kidney injury in patients with diabetes mellitus and multivessel disease undergoing coronary revascularization: Results from the FREEDOM trial.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 10 2019
Historique:
received: 12 11 2018
revised: 22 04 2019
accepted: 23 05 2019
pubmed: 25 6 2019
medline: 10 7 2020
entrez: 25 6 2019
Statut: ppublish

Résumé

The incidence and prognostic significance of acute kidney injury (AKI) in patients with diabetes mellitus and multivessel coronary artery disease undergoing coronary revascularization is not well known. The current analysis included patients randomized to PCI vs. CABG as part of the FREEDOM trial. We sought to examine the impact of AKI and its predictors in diabetic patients with multivessel coronary artery disease undergoing PCI vs. CABG. We conducted a pre-specified subgroup analysis of the FREEDOM trial to examine the incidence, correlates and impact of AKI according to revascularization strategy. AKI predictors were identified using multivariable logistic regression and associations between AKI and outcomes were examined using Cox regression. The primary endpoint was the composite occurrence of all-cause death, stroke or myocardial infarction at 5 years of follow-up. KI occurred more frequently in patients following CABG (15.6%) compared with PCI (9.1%) (p < 0.001). AKI was associated with a higher risk for major cardiovascular events (MACE) at 5 years (34.6% vs. 20.5%, p < 0.001), an effect that remained large and significant irrespective of CABG (HR = 2.18 95% CI 1.44-3.31, p ≤0.001) or PCI (HR = 2.08 95% CI 1.35-3.21, p < 0.0001). There was a non-significant interaction (p-value = 0.89) between the revascularization method and AKI, supporting that AKI is a significant risk factor in both revascularization methods. Although risk for AKI was higher in patients undergoing CABG, the impact of AKI on MACE was substantial irrespective of revascularization strategy. Preventive strategies to identify patients at risk for AKI are warranted to mitigate the long-term effects of this complication.

Sections du résumé

BACKGROUND
The incidence and prognostic significance of acute kidney injury (AKI) in patients with diabetes mellitus and multivessel coronary artery disease undergoing coronary revascularization is not well known. The current analysis included patients randomized to PCI vs. CABG as part of the FREEDOM trial. We sought to examine the impact of AKI and its predictors in diabetic patients with multivessel coronary artery disease undergoing PCI vs. CABG.
METHODS
We conducted a pre-specified subgroup analysis of the FREEDOM trial to examine the incidence, correlates and impact of AKI according to revascularization strategy. AKI predictors were identified using multivariable logistic regression and associations between AKI and outcomes were examined using Cox regression. The primary endpoint was the composite occurrence of all-cause death, stroke or myocardial infarction at 5 years of follow-up.
RESULTS
KI occurred more frequently in patients following CABG (15.6%) compared with PCI (9.1%) (p < 0.001). AKI was associated with a higher risk for major cardiovascular events (MACE) at 5 years (34.6% vs. 20.5%, p < 0.001), an effect that remained large and significant irrespective of CABG (HR = 2.18 95% CI 1.44-3.31, p ≤0.001) or PCI (HR = 2.08 95% CI 1.35-3.21, p < 0.0001). There was a non-significant interaction (p-value = 0.89) between the revascularization method and AKI, supporting that AKI is a significant risk factor in both revascularization methods.
CONCLUSIONS
Although risk for AKI was higher in patients undergoing CABG, the impact of AKI on MACE was substantial irrespective of revascularization strategy. Preventive strategies to identify patients at risk for AKI are warranted to mitigate the long-term effects of this complication.

Identifiants

pubmed: 31230933
pii: S0167-5273(18)36664-6
doi: 10.1016/j.ijcard.2019.05.064
pmc: PMC6710128
mid: NIHMS1533001
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

197-202

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL092989
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL071988
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Eur Heart J. 2016 Dec 07;37(46):3440-3447
pubmed: 27572072
Ann Intern Med. 1998 Feb 1;128(3):194-203
pubmed: 9454527
BMC Nephrol. 2015 May 30;16:76
pubmed: 26025079
Am J Kidney Dis. 2007 Jul;50(1):1-4
pubmed: 17591518
Can J Cardiol. 2014 Oct;30(10):1177-82
pubmed: 25154806
Kidney Int. 2010 Oct;78(8):803-9
pubmed: 20686453
Nephrol Dial Transplant. 2008 Jun;23(6):1970-4
pubmed: 18178605
J Am Heart Assoc. 2014 May 01;3(3):e000784
pubmed: 24786143
Int J Cardiol. 2017 Jan 1;226:42-47
pubmed: 27783968
N Engl J Med. 2012 Dec 20;367(25):2375-84
pubmed: 23121323
Arch Intern Med. 2011 Feb 14;171(3):226-33
pubmed: 21325112
Circ Cardiovasc Interv. 2015 Jun;8(6):
pubmed: 26019142
J Am Coll Cardiol. 2014 Jan 7-14;63(1):62-70
pubmed: 24076297
Cardiorenal Med. 2015 Jun;5(3):191-8
pubmed: 26195971
Ann Thorac Surg. 2014 Sep;98(3):815-22
pubmed: 25086946
J Am Coll Cardiol. 2014 Sep 9;64(10):985-94
pubmed: 25190232
Arch Intern Med. 2012 Feb 13;172(3):246-53
pubmed: 22332157
Lancet. 2014 May 24;383(9931):1814-23
pubmed: 24856027
N Engl J Med. 2016 Dec 8;375(23):2223-2235
pubmed: 27797291
CMAJ. 2016 Oct 18;188(15):1076-1083
pubmed: 27297813
Circ Heart Fail. 2013 Jan;6(1):83-90
pubmed: 23230310
JACC Cardiovasc Interv. 2017 Feb 27;10(4):355-363
pubmed: 28231903
Circulation. 2009 May 12;119(18):2444-53
pubmed: 19398670
Circ Cardiovasc Interv. 2016 Sep;9(9):
pubmed: 27582110
J Nephrol. 2016 Apr;29(2):169-174
pubmed: 26861658
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Circ Cardiovasc Interv. 2015 Aug;8(8):e002475
pubmed: 26198286
Am Heart J. 2016 Jan;171(1):40-7
pubmed: 26699599
Cardiorenal Med. 2016 May;6(3):237-50
pubmed: 27275160
Diabet Med. 2012 May;29(5):614-21
pubmed: 22017349

Auteurs

Yaron Arbel (Y)

Department of Cardiology, Tel Aviv Medical Center, Affiliated with the University of Tel Aviv, Tel Aviv, Israel. Electronic address: yarona@tlvmc.gov.il.

Valentin Fuster (V)

Icahn School of Medicine at Mount Sinai, New York, USA; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

Usman Baber (U)

Icahn School of Medicine at Mount Sinai, New York, USA; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

Taye H Hamza (TH)

New England Research Institute (NERI), USA.

F S Siami (FS)

New England Research Institute (NERI), USA.

Michael E Farkouh (ME)

Peter Munk Cardiac Centre, and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH